Concateno bags another acquisition:
This article was originally published in Clinica
UK drug and alcohol testing company Concateno continues to grow its maritime customer base with the acquisition of CPL International Serviced, a provider of alcohol and drugs-of-abuse screening services, as well as immunisation and medical examinations, to the maritime industry. Concateno bought CPL for a cash-and-stock consideration of £840,000 ($1.7m). Liverpool-based CPL, which recorded annual revenues of £433,000 in 2006, is Concateno's fifth purchase this year and comes one month after the latter acquired Marconova, a Swedish lab testing company also focused on the maritime industry, for £2m (see Clinica No 1258, p 14).
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.